ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce today the signature of a lease for
Launch of Broker Offer to raise a maximum of £500,000
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Live Q&A: London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, invites shareholders to join the CEO, Suzy Dilly and
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce that the project subject to the Evaluation
Genflow (LSE: GENF) is pleased to announce it has entered into a research agreement with Magnitude Biosciences Limited (“Magnitude”), a UK-based, specialist biotechnology research organisation that supports drug discovery and
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today providing an update on its proposed sub-license agreement with
Patent portfolio strengthened with international patent application under the Patent Cooperation Treaty